Stemtech Corp (STEK) — SEC Filings
Stemtech Corp (STEK) — 13 SEC filings. Latest: 10-Q (Nov 19, 2025). Includes 6 10-Q, 5 8-K, 2 10-K.
View Stemtech Corp on SEC EDGAR
Overview
Stemtech Corp (STEK) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 19, 2025: Stemtech Corp (STEK) reported a net loss of $809,406 for the three months ended September 30, 2025, a significant improvement from the $1,170,480 net loss in the same period of 2024. However, net sales decreased to $852,300 in Q3 2025 from $1,031,630 in Q3 2024, representing an 17.38% decline. For t
Sentiment Summary
Across 13 filings, the sentiment breakdown is: 3 bearish, 10 neutral. The dominant filing sentiment for Stemtech Corp is neutral.
Filing Type Overview
Stemtech Corp (STEK) has filed 6 10-Q, 2 10-K, 5 8-K with the SEC between Jul 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (13)
| Date | Form | Description | Risk |
|---|---|---|---|
| Nov 19, 2025 | 10-Q | Stemtech's Sales Plunge 35% Amidst Going Concern Doubts | high |
| Aug 19, 2025 | 10-Q | Stemtech Corp Files 10-Q for Q2 2025 | low |
| Jul 17, 2025 | 10-Q | Stemtech's Q1 Loss Widens to $1M Amid Revenue Decline | high |
| Jun 30, 2025 | 10-K | Stemtech's Mounting Losses Raise Going Concern Doubts | high |
| Apr 14, 2025 | 8-K | Stemtech Corp. Reports Officer and Director Changes | medium |
| Jan 3, 2025 | 8-K | Stemtech Corp Files 8-K: Regulation FD Disclosure | low |
| Dec 6, 2024 | 8-K | Stemtech Corp Files 8-K for Material Agreement | medium |
| Dec 3, 2024 | 8-K | Stemtech Corp Enters Material Definitive Agreement | medium |
| Nov 19, 2024 | 10-Q | Stemtech Corp. Files Q3 2024 10-Q Report | low |
| Aug 27, 2024 | 10-Q | Stemtech Corp Files 10-Q for Q2 2024 | medium |
| Aug 19, 2024 | 8-K | Stemtech Corp. Changes Certifying Accountant | medium |
| Jul 16, 2024 | 10-Q | Stemtech Corp. Files Q1 2024 10-Q | medium |
| Jul 10, 2024 | 10-K | Stemtech Corp. Files 2023 Annual Report | low |
Risk Profile
Risk Assessment: Of STEK's 13 recent filings, 3 were flagged as high-risk, 6 as medium-risk, and 4 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $852,300 |
| Net Income | -$809,406 |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $255,416 |
| Operating Margin | -39.80% |
| Total Assets | $3,755,801 |
| Total Debt | $10,301,779 |
Industry Context
Stemtech operates in the global wellness and stem cell nutrition market, a sector focused on science-based products aimed at enhancing natural bodily renewal. The company leverages a network marketing model to distribute its products internationally. The industry is characterized by innovation in health supplements and a growing consumer interest in preventative health and longevity, but also faces scrutiny regarding product claims and marketing practices.
Top Tags
10-Q (5) · financials (4) · Net Loss (3) · quarterly-report (3) · Going Concern (2) · Revenue Decline (2) · Direct Selling (2) · Liquidity Risk (2) · material-agreement (2) · Working Capital Deficiency (1)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Sales (Q3 2025) | $852,300 | Decreased from $1,031,630 in Q3 2024, a 17.38% decline. |
| Net Sales (Nine Months 2025) | $2,418,271 | Decreased from $3,740,000 in the prior year, a 35.34% decline. |
| Net Loss (Q3 2025) | $809,406 | Improved from $1,170,480 in Q3 2024. |
| Net Loss (Nine Months 2025) | $2,564,412 | Improved from $3,372,986 in the prior year. |
| Accumulated Deficit | $33.4 million | As of September 30, 2025, indicating significant historical losses. |
| Working Capital Deficiency | $9.2 million | As of September 30, 2025, highlighting liquidity issues. |
| Expected Capital Raise | $5-7 million | Targeted from private placement of common stock by Q4 2025. |
| Convertible Debt Facility | $3 million | Expected to close by Q1 2026 for interim liquidity. |
| Annual Cost Reductions | $0.5 million | Identified through vendor renegotiations and overhead elimination. |
| Shares Outstanding | 231,975,027 | As of November 19, 2025, indicating potential for dilution. |
| Net Loss | $1.0M | Increased 100% from $0.5M in Q1 2024 |
| Revenue | $2.5M | Decreased 15% from $2.94M in Q1 2024 |
| Cash Flow from Operations | -$0.75M | Indicates persistent negative cash generation |
| Cash and Cash Equivalents | $1.2M | Decreased from $1.5M at Dec 31, 2024 |
| Revenue Decline | 15% | Year-over-year decrease in Q1 2025 |
Frequently Asked Questions
What are the latest SEC filings for Stemtech Corp (STEK)?
Stemtech Corp has 13 recent SEC filings from Jul 2024 to Nov 2025, including 6 10-Q, 5 8-K, 2 10-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of STEK filings?
Across 13 filings, the sentiment breakdown is: 3 bearish, 10 neutral. The dominant sentiment is neutral.
Where can I find Stemtech Corp SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Stemtech Corp (STEK) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Stemtech Corp?
Key financial highlights from Stemtech Corp's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for STEK?
The investment thesis for STEK includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Stemtech Corp?
Executive information for Stemtech Corp is extracted from SEC filings as they are enriched with AI analysis.
What are the main risk factors for Stemtech Corp stock?
Of STEK's 13 assessed filings, 3 were flagged high-risk, 6 medium-risk, and 4 low-risk.
What are recent predictions and forward guidance from Stemtech Corp?
Forward guidance and predictions for Stemtech Corp are extracted from SEC filings as they are enriched.